1 terminated, 1 unknown, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Everett Meyer: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant donor regulatory T lymphocytes, laboratory biomarker analysis - Graft Versus Host Disease | Phase 1 | Withdrawn | Everett Meyer | 2015-08-06 | 2023-11-22 | |
| Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs. Immune Tolerance - ESRD | Phase 1 | Unknown | Everett Meyer | 25 | 2010-07-14 | 2023-06-18 |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Regulatory T-cells, Conventional T-cells, Melphalan - Leukemia, Acute, Chronic Myelogenous Leukemia (CML) | Phase 1 / Phase 2 | Terminated | Everett Meyer | 10 | 2009-06-01 | 2018-06-27 |
Graft vs Host Disease (1) · Kidney Failure, Chronic (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Antilymphocyte Serum (1) · Immune Tolerance (1) · Kidney Transplantation (1) · Melphalan (1) · Thiotepa (1) · thymoglobulin (1)
United States (3)
Everett H Meyer, MD, PhD (1) · Stephan Busque, MD,MS (1)
P01HL075462 (1)